Correct. In the Zacks Small-Cap Research April 21st article by Jason Napodano: "RVX: Initiating Coverage of Resverlogix Corp.: A Clinical Stage Cardiovascular Company with an Epigenetics Platform" it was stated that Resverlogix was meeting with the European Medicines Agency in April and the FDA in May.
BDAZ